Discussion
Ocrevus (ocrelizumab) and Kesimpta (ofatumumab) are both highly effective at preventing relapses and disability worsening in people with relapsing-remitting multiple sclerosis (RRMS) in real-world clinical practice, though data show small differences in their clinical profiles. While Ocrevus was linked to fewer relapses and Kesimpta to a lower…